Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
Michael J Davies,1 Katherine W Merton,1 Ujjwala Vijapurkar,2 Dainius A Balis,2 Mehul Desai2 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Janssen Research & Development, LLC, Raritan, NJ, USA Objective: Metabolic syndrome refers to a collection of risk factors associated with the d...
Enregistré dans:
| Auteurs principaux: | Davies MJ, Merton KW, Vijapurkar U, Balis DA, Desai M |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2017
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/0fab17479a684dd3b6063eb27630e72e |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Canagliflozin review – safety and efficacy profile in patients with T2DM
par: Jakher H, et autres
Publié: (2019) -
Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
par: Seko Y, et autres
Publié: (2018) -
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
par: Santos Cavaiola T, et autres
Publié: (2018) -
Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
par: Takahara M, et autres
Publié: (2020) -
Clinical utility of metabolic syndrome severity scores: considerations for practitioners
par: DeBoer MD, et autres
Publié: (2017)